about
Sipuleucel-T (Provenge®) for castration-resistant prostate cancerPersonalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignanciesAutologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapyNovel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures.Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.Engineering nano- and microparticles to tune immunityEnhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Tumor evasion from T cell surveillance.Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm.Ipilimumab in prostate cancer.Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.Unleashing the therapeutic potential of human kallikrein-related serine proteases.Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.Immunotherapy for prostate cancer enters its golden age.A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy developmentEffects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.Antitumor effects of baculovirus-infected dendritic cells against human pancreatic carcinoma.The evolving landscape in advanced penile cancer.AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.The role of immunotherapy in oncology.The potential detrimental effect of corticosteroids in prostate cancer.Sequential therapies in castration-resistant prostate cancer.New agents for prostate cancer
P2860
Q26991753-E6E6E2F1-4EA7-4586-8BB1-942CCF8E4681Q33361158-B4EA5DC3-A1AF-4B1A-B457-6700D8F5129CQ33600115-E317CC4C-D1D6-4E4F-B0D5-496370A28B17Q34429991-2EB5C55F-69D2-4190-8FBC-632955240199Q34442600-B6192ECD-59A4-4BA3-9187-563A0617E7EFQ34599387-5A297CE6-27FC-45A2-90ED-40044049E0F1Q36580194-B464C0D3-FF72-4732-A817-2D9A4F24C854Q36833481-DF39FD2F-7BE5-425B-87CA-5F78C0BD8BF8Q37205125-3E9679C5-6FDC-4C35-9364-3C13FE80149EQ37521861-3B6F66CA-8D37-44A6-ABE2-5C80485EF4EBQ37591900-67BFB6E1-9B91-4FE3-A43D-8C9F7BB0F1CCQ37709535-1A3C00EC-90C3-4984-B01D-08FDE1670814Q37970674-D1183FEB-4285-42E7-AA60-3BFED7F681EEQ37989569-FF6F2F4B-8ECF-4D2D-947B-B2FC97F6EB79Q38069640-195BB567-2E2C-459A-91F8-4DA471188B0DQ38107203-5072D182-0AA9-452E-9DF7-5B7C98CDCE50Q38177689-F163E706-D162-471A-A598-5D5984987217Q38289426-3B8F3274-A853-4FD0-A4CD-089D59F985B9Q38362486-FE34E072-8EFC-4CA7-AC9B-285EC294C438Q39155556-9EF48845-5A4D-4C11-88A0-40DAD0809B62Q39577914-DF16C961-E9A4-4CF4-84E8-40743C6C77ADQ40887427-E435897A-88B4-4A2D-A697-6338B8CC6CB4Q41636538-30E94080-C462-49D8-92CA-8DBA11BEF859Q41915850-ECA9A34C-252B-451D-A95C-6E59B9BED0DCQ42015004-F69B596B-7DD7-4A29-AF29-5CF420DBF4DAQ42207160-75D6FA7E-7917-4D3F-8F74-4D3CC8E7C000Q42358603-7AD265E2-99AE-481C-AA74-DAB83D51FE4DQ44534208-3269C601-A8B9-4484-9929-89F99E4E15ADQ45901690-D7012B86-90A8-4007-B280-1D8A55A3D0EDQ48376397-FDFB5094-6C74-4C4B-BD38-C5E3DF6BB1EBQ48986862-3BFD85A3-6CC4-4F54-BF7B-1DF6AD6653F0Q49056452-2E95E788-B95E-448D-A0FF-D46111C4BD6CQ55981202-43423F47-8FD9-48F6-BA09-D8F5A18664C3
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Immunotherapy for the treatment of prostate cancer.
@ast
Immunotherapy for the treatment of prostate cancer.
@en
Immunotherapy for the treatment of prostate cancer.
@nl
type
label
Immunotherapy for the treatment of prostate cancer.
@ast
Immunotherapy for the treatment of prostate cancer.
@en
Immunotherapy for the treatment of prostate cancer.
@nl
prefLabel
Immunotherapy for the treatment of prostate cancer.
@ast
Immunotherapy for the treatment of prostate cancer.
@en
Immunotherapy for the treatment of prostate cancer.
@nl
P2860
P1476
Immunotherapy for the treatment of prostate cancer.
@en
P2093
Giuseppe Di Lorenzo
P2860
P304
P356
10.1038/NRCLINONC.2011.72
P407
P577
2011-05-24T00:00:00Z